Unusual 11 Mid-Day Movers 11/08: (DUSA) (RST) (PRMW) Higher; (CPRX) (BCRX) (PRSS) Lower

Catyalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) 61.5% LOWER; announced top-line results from its U.S. Phase II(b) clinical trial evaluating the use of CPP-109 (vigabatrin) to treat cocaine addiction. The data from the trial showed that CPP-109 did not meet the primary endpoint -- that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 8 and 9). The data also showed that the two key secondary endpoints, a significantly larger increase in cocaine negative urines and a significant decrease in the weekly fraction of use days in medication-treated subjects during weeks 3-9, also were not met.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) 40.0% LOWER; reported Q3 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $4.63 million.

DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) 37.6% HIGHER; Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals entered into a definitive agreement under which Sun Pharma will acquire DUSA for $8 per share.

Rosetta Stone (NYSE: RST) 21.7% HIGHER; reported Q3 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $34.3 million versus the consensus estimate of $62.2 million.

Primo Water Corp. (Nasdaq: PRMW) 20.8% HIGHER; reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $26.2 million versus the consensus estimate of $26.35 million.

Cafepress (Nasdaq: PRSS) 20.3% LOWER; reported Q3 EPS of ($0.01), $0.07 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $43.6 million versus the consensus estimate of $43.6 million. Sees Q4 2012 EPS of $0.16 - $0.32, versus the consensus of $0.36 and revenue of $80 - $87 million, versus the consensus of $79.75 million.

Savient Pharmaceuticals (Nasdaq: SVNT) 20.0% LOWER; reported Q3 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $5.85 million.

Pluristem Therapeutics Inc. (Nasdaq: PSTI) 19.5% LOWER; has successfully completed the integration and testing of its new scaled-up formulation and manufacturing process to produce high-yield quantities of its Placental eXpanded (PLX) cells for clinical trials and potential commercial use. The increased automation and larger scale process allows the company to produce billions of live cells simultaneously.

FalconStor Software, Inc. (Nasdaq: FALC) 19.4% HIGHER; reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $16.47 million. Hired Wells Fargo to explore alternatives.

Aeroflex Holdings (NYSE: ARX) 19.3% HIGHER; reported Q1 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $141.2 million versus the consensus estimate of $137.2 million. Sees Q2 2013 EPS of $0.06 - $0.09, versus the consensus of $0.08. Aeroflex Holdings sees Q2 2013 revenue of $147 - $155 million, versus the consensus of $151.0 million.

EnergySolutions (NYSE: ES) 18.6% HIGHER; reported Q3 EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $444.2 million versus the consensus estimate of $423.23 million.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• Domino's Pizza (DPZ) PT Raised to $475 at Wells Fargo
• Walt Disney (DIS) PT Raised to $141 at Wells Fargo